Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance and pharmacokinetics study of GSBR-1290 with a [14C] microtracer in healthy participants
NL-OMON60449Phase 1Completed
- Sponsor
- Structure Therapeutics
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aleniglipron, sponsored by Structure Therapeutics. Started Jun 2024; status: completed.
02
Drugs
aleniglipron
Beyond the preview
Go deeper on NL-OMON60449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60449.